Results 61 to 70 of about 56,599 (248)

Late‐Onset Rheumatoid Arthritis and Air Pollution in the Multiethnic Cohort

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the effects of ambient air pollution on rheumatoid arthritis (RA) incidence in a racially and ethnically diverse population. Methods This analysis included 42,152 California Multiethnic Cohort participants, aged ≥65 years (>70% African American and Latino adults) who were enrolled in the Fee For Service component of Medicare (2001–
Anna H. Wu, Chiuchen Tseng, Song‐Yi Park, Daniel O. Stram, Kami White, Jun Wu, Cheryl Vigen, Veronica W. Setiawan, Xian Yu, Steven Gazal, Christopher Haiman, Lynne Wilkens, Loïc Le Marchand, Iona Cheng, William Stohl   +14 more
wiley   +1 more source

Treatment with Etanercept in a Patient with Rheumatoid Arthritis-Associated Interstitial Lung Disease

, 2011
We report a case of a 52-year-old woman with a 1-year history of rheumatoid arthritis-associated interstitial lung disease referred to hospital because of aggravated pulmonary symptoms in spite of intensive treatment including prednisone, azathioprine ...
Jian-hua Xu, Sheng-qian Xu, Changhai Ding, Yu Wang   +3 more
core   +1 more source

Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation

, 2020
Background: Previous open-label studies showed that chronic post-stroke pain could be abated by treatment with perispinal etanercept, although these benefits were questioned.
Bonham, Mikaela D, Smith, Ashley D, King, Liam D, Ferguson, Samantha, Ralph, Stephen J, Weissenberger, Andrew, Bonev, Ventzislav, Goodman-Jones, Adrienne A, Espinet, Anthony J   +8 more
core   +1 more source

Risk Assessment of Etanercept in Mice Chronically Infected With Toxoplasma gondii

Frontiers in Microbiology, 2018
Toxoplasma gondii (T. gondii) is a zoonotic parasite that severely harms the health of the host. The cysts of T. gondii can reactivate from bradyzoites to tachyzoites, if the individual develops low or defective immunity, causing lethal toxoplasmosis ...
Jing Yang, Luyao Wang, Dongmei Xu, Ding Tang, Senyang Li, Fen Du, Lixia Wang, Junlong Zhao, Rui Fang   +8 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

, 2011
ObjectiveTo investigate the relationship between serum etanercept levels and clinical response.MethodsIn 292 etanercept-treated patients with rheumatoid arthritis clinical and pharmacological data were determined at baseline and after 1, 4 and 6 months ...
B A Dijkmans, A E Voskuyl, M H Hart, L Aarden, G J Wolbink, M T Nurmohamed, A Jamnitski, C L Krieckaert   +7 more
core   +1 more source

Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging

BMC Research Notes, 2009
Background The cytokines interleukin-1 and tumor necrosis factor (TNF), and the cytokine blocker interleukin-1 receptor antagonist, all have been demonstrated to enter the cerebrospinal fluid (CSF) following peripheral administration.
Chen Xiaoyuan, Chen Kai, Tobinick Edward L   +2 more
doaj  

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, EarlyView.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic:results from the BSRBR-RA

, 2023
OBJECTIVES: Etanercept biosimilars show comparable efficacy to their originators among biologic-naïve patients with RA in RCTs. Nationwide guidelines have obligated prescribing of etanercept biosimilars from 2016 resulting in significant cost-savings ...
Tsoi, Man-Fung, Tsoi, Man Fung, Zhao, Sizheng Steven, Watson, Kath D, Kearsley-Fleet, Lianne; id_orcid, Kearsley-Fleet, Lianne, Hyrich, Kimme L, Watson, Kath, Lunt, Mark, Rokad, Aasiyah, Lunt, Mark; id_orcid, Hyrich, Kimme, Zhao, Sizheng; id_orcid   +12 more
core   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source